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Abstract 
Pancreatic cancer remains an overwhelmingly fatal disease with less than 5% of patients 
surviving beyond 5 years, largely due to our lack of understanding of the complexity of the 
disease. Many recent reports have begun to highlight the potential role that stromal cells—
fibroblasts in particular—may have on pancreatic tumor cell biology and this report provides 
data that supports the theory of tumor-stroma co-evolution in pancreatic cancer. Here we use a 
novel mouse model to show that Ets-2 in the tumor-associated stroma promotes pancreatic tumor 
initiation and development. We observed a decrease in tumorigenesis events such as acinar-to-
ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia (PanIN) lesions when Ets-2 is 
conditionally deleted in pancreatic cancer associated fibroblasts (CAFs). To determine how Ets-2 
in fibroblasts is able to effect tumor progression, we harvested pancreatic CAFs from Ets-2 
deleted and Ets-2 intact tumor bearing mice and performed microarray gene expression analysis. 
We found that Ets-2 deleted CAFs had a significantly altered secretome that crucially lacked 
tumor necrosis factor alpha (TNF-α), a known pro-tumor ligand in pancreatic carcinogenesis. 
Furthermore, ChIP analysis showed that Ets-2 binds the proximal promoter of TNF-α to directly 
regulate its expression. Thus, Ets-2 ablation in pancreatic fibroblasts delays pancreatic tumor 
initiation by decreasing the pro-tumor ligand TNF-α. This report shows for the first time that 
deleting a gene in pancreatic fibroblasts causes a change in tumor-stroma co-evolution and that 
Ets-2 is able to act as a novel oncogene in cancer associated fibroblasts to promote pancreatic 
carcinogenesis. 
Introduction 
Pancreatic cancer is an overwhelmingly fatal disease with approximately 95% of patients dying 
within 5 years of diagnosis [Siegel et al., 2013]. Moreover, our lack of knowledge in pancreatic 
cancer is evident in the fact that it has the least significant improvement in overall survival rate 
amongst all cancers over the last 35 years [Siegel et al., 2013]. Early studies on this disease 
focused on uncovering the genetics behind tumor formation, which led to the discovery of 
KRAS, CDKN4A, TP53, and SMAD4 mutations within tumor cells [Almoguera et al., 1998, 
Caldas et al., 1994, Redston et al., 1994, Hahn et al., 1996]. These studies were all performed in 
order to better understand the genetics behind Pancreatic Ductal Adenocarcinoma (PDAC), the 
most clinically prevalent form of pancreatic cancer. Recently, researchers have begun to study 
earlier events in pancreatic tumorigenesis and it has become apparent that PDAC originates from 
premalignant lesions termed Pancreatic Intraepithelial Neoplasms (PanIN) that arise from 
activating KRAS mutations in the epithelium [Hezel et al., 2006]. These efforts have also 
uncovered potential tumor initiating transformation events where pancreatic acinar epithelial 
cells trans-differentiate into ductal cells (termed acinar-to-ductal metaplasia, ADM) and then 
progress to PanIN [De La O et al., 2008]. Importantly, this transition from ADM to PanIN to 
PDAC is associated with a dramatic expansion of the pancreatic stroma, particularly in the 
fibroblast compartment. Thus far, the genetics of the tumor microenvironment during pancreatic 
tumor formation have been largely ignored. This report looks to further the understanding of the 
role that the pancreatic stroma plays in epithelial transformation using genetically engineered 
mouse models. 
Ets-2 (v-ets erythroblastosis virus E26 onocogene homologue 2) is a proto-oncogene in the Ets 
family of transcription factors that is overexpressed in a variety of cancers, including PDAC [Ito 
et al., 2002]. Furthermore, Ets-2 has previously been shown to play a driver role in CAFs in 
mammary tumorigenesis [Trimboli et al., 2009]. However, it has yet to be determined the role 
that stromal Ets-2 plays in pancreatic tumor development. In this study, we describe the 
generation of a genetically engineered mouse model of fibroblast-specific knockout of Ets-2 in 
Kras-driven pancreatic tumors. Notably, we identify an oncogenic role for Ets-2 in pancreatic 
CAFs and show that loss of Ets-2 in fibroblasts leads to decreased PanIN and ADM lesions. 
Gene expression analysis of Ets-2 deleted pancreatic CAFs indicates that the secretome is 
misregulated upon loss of Ets-2, specifically showing a decrease in the pro-tumor ligand TNF-α. 
We also show that Ets-2 directly regulates TNF-α production at the transcriptional level in 
pancreatic CAFS and loss of Ets-2 leads to decreased Tnfa expression. Collectively, this report 
shows that pancreatic CAFs are dependent on Ets-2 in order to create a TNF-α induced pro-
tumor microenvironment. 
Materials and Methods 
Mice 
The Mist1-KrasG12D, Ets-2LoxP (herein referred to as Ets-2fl), Ets-2db, and Fsp-Cre alleles have all 
been previously described [Tuveson et al., 2006, Wei et al., 2009, Yamamoto et al., 1998, and 
Trimboli et al., 2008]. The use of animals was in compliance with federal and University 
Laboratory Animal Resources (ULAR) at The Ohio State University regulations and was 
conducted under the protocol (2007A0120-R1) which was reviewed and approved by the Ohio 
State University Institutional Animal Care and Use Committee (IACUC).  
Tumor Studies 
Mist1-KrasG12D tumor bearing mice were sacrificed from 15-30 weeks after birth as indicated. At 
the time of euthanasia, total body weight and pancreas/tumor weight were documented. 
Pancreata, liver, and lung were removed and either frozen in OCT or fixed in formalin for 48-72 
hours for subsequent histological processing by the Soild Tumor Pathology Core at OSU.  
Pancreatic Cancer Associated Fibroblast Isolation 
Mist1-KrasG12D mice were euthanized and individual pancreata were removed and minced in 
5mg/ml Type II collagenase in PBS. After mincing, pancreata were dissociated by shaking at 225 
RPM at 37°C for 60 minutes. Cells were washed with complete Dulbecco's Modified Eagle 
Medium (DMEM, containing 10% FBS) and then pelleted by centrifugation at 200xg for 5 
minutes at 4°C. Cell pellets were resuspended in 5ml complete DMEM and allowed to gravity 
precipitate at room temperature for 10 minutes. After precipitation, top 3ml of solution was 
discarded and cellular pellet was resuspended in up to 5ml of complete DMEM, thus constituting 
one round of gravity precipitation. An additional round of gravity precipitation was conducted 
and the final cellular pellet was seeded. 24-hours post seeding media was replaced with complete 
DMEM. To further purify fibroblasts cultures, selective trypsonization was utilized where 0.25% 
trypsin was added to PBS-washed plated for 90 seconds and then fibroblasts were collected and 
re-seeded on a new plate. Fibroblast purity was confirmed by immunofluorescence as noted.  
Immunofluorescence and Histological Staining of Tissue Sections 
After removal from the body, tissue was immediately frozen in OCT or fixed in formalin for 48 
hours, transferred to 70% ethanol and then paraffin embedded. Frozen or embedded tissue was 
subsequently sectioned and mounted on glass slides for further analysis. Sections were processed 
with xylenes and ethanol prior to DAKO antigen retrieval in a streamer for 30 minutes. Sections 
were blocked with DAKO protein block and tissues were stained with anti- F4/80 (Invitrogen), -
vimentin (Cell Signaling), beta amylase (Cell Signaling), -cytokeratin 19 (Iowa Developmental 
Studies Hybridoma Bank), and -Ki67 (Abcam) as noted. Hematoxylin and eosin (H&E) and 
Masson’s Trichrome staining was performed by the Solid Tumor Pathology Core at OSU. 
Immunofluorescence Staining of Fibroblast Cultures 
Cells were grown on glass cover slips to 90% confluence and fixed using 4% PFA. Fixed cells 
were blocked using DAKO protein block and stained with anti-α smooth muscle actin (Abcam) 
and –cytokeratin 19 (Iowa Developmental Studies Hybridoma Bank) as noted. 
RNA Isolation and Quantitative Real Time PCR 
RNA was isolated using Trizol reagent (Invitrogen), treated with DNase I (Ambion), and cDNA 
was generated using Superscript III Reverse Transcription (Invitrogen) as per the manufacturer’s 
specifications. Quantitative real time PCR was performed using primer specific Roche Universal 
Probe Library system on Applied Biosystems Step One Plus real time PCR systems. 
Gene Set Enrichment Analysis (GSEA) 
GSEA v2.0 was downloaded from the BROAD institute (http://www.broadinstitute.org/gsea) and 
used to determine molecular pathways that were misregulated upon deletion of Ets-2. Gene sets 
were obtained from Broad institute GSEA and ToppGene Suite databases. Statistical analysis 
was determined using 1,000 random permutations of each gene set to obtain a nominal P value 
and normalized enrichment score (NES). 
Results 
Mist1-KrasG12D Mice Developed Dramatic Stromal Reaction 
Mist-KrasG12D mice have been previously shown to develop mixed differentiated pancreatic 
carcinoma with the accompaniment of a rich stromal component, similar to human tumors 
[Tuveson et al., 2006]. We further characterized the Mist1-KrasG12D mouse tumor model by 
performing a time-course analysis of the stromal reaction as the disease progresses. We 
monitored tumor histology on a bi-weekly basis and determined that 23 weeks of age 
consistently lead to increased collagen deposition in Mist1-KrasG12D mice pancreata relative to 
wild type mice, as measured by Masson’s Trichrome staining (Figure 1A-B). Histologically, 23-
week old Mist1-KrasG12D mice have developed PanIN and ADM lesions, but are still 
premalignant. Furthermore, we showed a dramatic increase in SMA+ fibroblasts and F4/80+ 
macrophages in 23-week old Mist1-KrasG12D pancreata (Figure 1C-D). These data indicate that 
the Mist1-KrasG12D mouse pancreatic tumor model is a valid system for us to study the role of 
pancreatic CAFs in tumor initiation and development.  
Ets-2 is Efficiently Deleted in Pancreatic Cancer Associated Fibroblasts 
In order to conditionally delete Ets-2 in pancreatic fibroblasts in the Mist-KrasG12D pancreatic 
tumor model, we generated Mist1-KrasG12D; Fsp-Cre; Ets-2db/fl experimental mice and Mist1-
KrasG12D; Ets-2db/fl control mice. We utilized the previously validated Ets-2db null allele that lacks 
the DNA binding domain and is functionally null in order to increase the efficacy of our cre-loxP 
deletion of the Ets-2fl allele [Wallace et al., 2013, Trimboli et al., 2009, Zabuawala et al., 2010]. 
Using a novel procedure for harvesting pancreatic fibroblasts (Figure 2A), we were able to 
isolate over 99% pure populations of fibroblasts as measured by the expression of fibroblast 
marker SMA and lack of expression of epithelial marker cytokeratin 19 (Figure 2B). 
Furthermore, we showed that these cells also expressed alternative fibroblast marker vimentin 
and lacked expression of cytokeratin 8 (data not shown). After verifying that novel method of 
purifying fibroblasts was effective, we performed conventional genotyping PCR on genomic 
DNA isolated from wild type, Mist1-KrasG12D; Fsp-Cre; Ets-2db/fl, and Mist1-KrasG12D; Ets-2db/fl 
fibroblast cultures. We showed that Ets-2 was deleted exclusively in pancreatic fibroblasts from 
Mist1-KrasG12D; Fsp-Cre; Ets-2db/fl mice using loxP-recombination specific primers (Figure 2C, 
left). In order to show that the Ets-2fl was also excised in vivo, we isolated genomic DNA from 
formalin fixed paraffin embedded (FFPE) pancreatic tissue sections from Mist1-KrasG12D; Fsp-
Cre; Ets-2db/fl, and Mist1-KrasG12D; Ets-2db/fl mice and performed genotyping using the same 
recombination specific PCR primers (Figure 2C, right). We saw cre deletion specific amplicons 
exclusively in Mist1-Kras; Fsp-Cre; Ets2db/fl animals. To confirm that genomic Ets-2 deletion 
leads to decreased mRNA production, we performed quantitative real time PCR on RNA isolated 
from Mist1-KrasG12D; Fsp-Cre; Ets-2db/fl, and Mist1-KrasG12D; Ets-2db/fl fibroblasts (Figure 2D). 
Importantly, our cre-deleted mice have one remaining Ets-2db allele that will make mRNA, but 
not functional protein [Yamamoto et al., 1998]. Therefore, we expect to see ~50% decrease in 
cre-deleted Ets-2db/fl mice, indicating high recombination efficiency of the Ets-2fl allele. 
Collectively, this data shows that we can generate pure populations of murine pancreatic CAFs 
and that Ets-2fl alleles are excised in fibroblasts in Mist1-KrasG12D; Fsp-Cre; Ets-2db/fl mice. 
Loss of Ets-2 in Pancreatic Cancer Associated Fibroblasts Decreases Premalignant Lesions in 
the Mist1-KrasG12D Murine Pancreatic Tumor Model. 
In order to show the effect of Ets-2 loss in pancreatic fibroblasts on tumorigenesis events, we 
monitored pancreatic tumor development by H&E staining from Mist1-KrasG12D; Fsp-Cre; Ets-
2db/fl, and Mist1-KrasG12D; Ets-2db/fl mice at 23 weeks of age. Histological analysis showed that 
mice lacking Ets-2 in pancreatic CAFs have delayed onset of Pancreatic Intraepithelial 
Neoplastic (PanIN) lesions relative to Ets-2 intact age-matched controls (Figure 1A). 
Additionally, we showed that the same mice have significantly decreased acinar-to-ductal 
metaplastic (ADM) lesions as measured by ducts that are double positive for epithelial cell 
marker cytokeratin 19 (K19) as well as acinar cell marker amylase (Figure 1B). In order to 
explain the decrease in premalignant lesions, we stained pancreatic sections for the ductal cell 
marker cytokeratin 19 and the cellular proliferation marker Ki67 and showed that Ets-2 
fibroblast deleted mice had decreased percentage of proliferating ductal tumor cells. Thus, these 
results indicate that fibroblast specific deletion of Ets-2 in the pancreas leads to a significant 
delay in premalignant PanIN and ADM lesion formation due to a decrease in the proliferation 
potential of the pancreatic epithelium. 
Ets-2 Regulates a Pro-Tumor Secretome in Pancreatic Cancer Associated Fibroblasts 
To understand how deleting Ets-2 may change the proliferation potential of the adjacent tumor 
cell, we isolated CAFs from Mist1-KrasG12D; Fsp-Cre; Ets-2db/fl, and Mist1-KrasG12D; Ets-2db/fl 
pancreata and performed microarray (Figure 4A). Gene expression analysis followed by Gene 
Set Enrichment Analysis (GSEA) determined that Ets-2 deletion significantly altered the 
secretory pathway within fibroblasts (Figure 4B). We generated a heat map to depict significant 
changes in select genes whose secreted protein products may act upon the adjacent epithelia 
(Figure 4C). Not surprisingly, many pro-tumor secreted factors as well as matrix remodelers 
such as the MMP, CXCL, and CCL were decreased in Ets-2 deleted fibroblasts. This result 
mimicked previously described results for Ets-2 deletion in mammary tumor models. 
Interestingly a novel fibroblast Ets-2 regulated factor, tumor necrosis factor alpha (TNF-α), 
appeared in this analysis to be downregulated at the mRNA level in our microarray upon Ets-2 
deletion (Figure 4C). Additionally, GSEA showed that TNF-α pathways was significantly altered 
upon Ets-2 deletion, further confirming that Ets-2 regulates TNF-α. This result was significant 
given the previously published importance of TNF-α in many pro-tumor processes in pancreatic 
and other cancers [Balkwill et al., 2006, Liou et al., 2013]. 
Ets-2 Drives TNF-α Production in Pancreatic Fibroblasts 
To confirm the microarray result that Ets-2 regulates TNF-α expression, we performed 
quantitative real time PCR and showed that Tnfa mRNA was significantly downregualted in Ets-
2 deleted fibroblasts (Figure 5B).  This result indicates that Ets-2 regulates Tnfa expression, but 
does not prove that Ets-2 directly binds to and induces transcription of Tnfa. However, Ets-2 has 
been speculated to bind to the proximal promoter of Tnfa due to the consensus binding sequence 
-115 basepairs upstream of the transcription start site (TSS), but no lab has directly shown Ets-2 
binding to our knowledge. To demonstrate that Ets-2 directly regulates Tnfa expression by 
binding to its proximal promoter, we performed Chromatin Immunoprecipitation (ChIP) for Ets-
2 and IgG control and performed quantitative real time PCR for Tnfa. We showed significant 
enrichment for Ets-2 at the Tnfa promoter relative to IgG pulldown in Ets-2 intact CAFs. 
Moreover, we confirmed lack of Ets-2 pulldown in Ets-2 knockout CAF lines (Figure 5C). 
Together this data suggests that Ets-2 regulates Tnfa expression by directly binding to its 
promoter and inducing transcription. 
Discussion 
Ets-2 has been documented to play an important role in the effect of the stroma on epithelial 
transformation and tumorigenesis of cancers of other organ systems [Wallace et al., 2013, 
Bronisz et al., 2011, and Trimboli et al., 2009]. These results are not surprising given the known 
Ets-2-mediated pathways such as extracellular matrix (ECM) remodeling, angiogenesis, cellular 
proliferation, and cell migration [Wallace et al., 2013]. Additionally, these pathways have been 
speculated to play a role in the development of pancreatic tumors and we hypothesized that 
disrupting Ets-2 signaling may influence tumor development.  
In this study, we demonstrate that Ets-2 is a key component in the promotion of pancreatic tumor 
formation by fibroblasts, by showing significantly delayed tumorigenesis events in fibroblast 
Ets-2 conditional fibroblast deletion mice. This finding is significant because it is the first time 
that conditional deletion of a gene in fibroblasts has been shown to affect pancreatic tumor 
growth and development. Additionally, we have provided mechanistic insight into how Ets-2 in 
fibroblasts is able to influence epithelial cell malignancy by showing that Ets-2 directly binds to 
the Tnfa promoter. Thus, deletion of Ets-2 in fibroblasts leads to decreased TNF-α production, 
which is a known pancreatic tumorigenesis modulator [Liou et al., 2013]. Currently ongoing 
studies are required to show that fibroblast-derived TNF-α is necessary and/or sufficient to 
induce ADM and PanIN both in vitro and in vivo. Additionally, we will further elucidate the 
mechanistic details of the Ets-2 regulated pathways through co-culture experiments. In brief, we 
will co-culture pancreatic epithelial cells and pancreatic fibroblasts (either intact or deleted for 
Ets-2) and measure the effect of deleting Ets-2 upon epithelial cell proliferation and in vitro 
ADM formation, as previously described (in vitro ADM paper). Additionally, we will harvest 
conditioned media from Ets-2 intact or deleted fibroblasts and treat normal pancreatic epithelial 
cells to see if direct cell-to-cell contact is required for the transformative abilities of fibroblasts. 
Together, these experiments will develop a more complete story of the role of pancreatic 
fibroblast Ets-2 and provide mechanistic insight into the pathways that Ets-2 regulates in 
pancreatic CAFs. 
In conclusion, this study has established an oncogenic role for Ets-2 in pancreatic fibroblasts 
through a TNF-α mediated mechanism. This result shows for the first time that deleting a gene in 
pancreatic fibroblasts is able to influence the fate of the tumor cell and supports the hypothesis 
that pancreatic cancer associated fibroblasts play a driver role in determining the fate of the 
tumor cell. 
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